Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…d over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/…
…Skin was the most common site of primary malignancy (n=67;62%). Pembrolizumab (n=44;40.7%) and Ipilimumab/Nivolumab in combination (n=44;40.7…
…l melanoma treated with lymph node resection, radiotherapy, and pembrolizumab in 2019.On examination, she was afebrile and normotensive, with…
…sk lesions. Immune checkpoint inhibitors (ICIs) (cemiplimab and pembrolizumab) represent a promising therapeutic option for cases of unresect…
…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …
…c MGMT-deficient G1/G2 PanNET treated with TMZ, with or without capecitabine, reportedly experienced histological progression to G3 disease …
…rable (figure 2). Consistent with the tumor-activated design of vilastobart, treatment was generally well-tolerated: overall (n=44), 11 pat…
…hort 1 has 43 patients all with HLA A2 receiving ipilimumab and nivolumab with 10 doses of intra-muscular SCIB1 over 24-months. Cohort 3 …
…unother Cancer. 2019;7:214.Wong MK, Milhem MM, Sacco JJ, et al. RP1 combined with nivolumab in advanced anti-PD-1-failed melanoma (…
…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…
…de combination ipilimumab and nivolumab, nivolumab monotherapy, pembrolizumab, and combination relatimab and nivolumab. Regarding hospitaliza…
…nt with advanced NSCLC, acquired before and after initiation of Pembrolizumab. Post-ICI treatment, [18F]F-AraG uptake increased across multip…